<p>Although the prevalence of TB decreased significantly after the implementation of the One-J program, the overall prevalence remains high. Addressing modifiable risk factors such as functional status, INH use, CD4 count, and WHO clinical stage is crucial in reducing TB risk among ART patients.</p>